2024 was an exciting year for #lungcancer advances! As we mark the 20th anniversary of the discovery of EGFR's role in NSCLC, we celebrate this era of #precisionmedicine that is extending and improving patients' lives. #LCSM
@oncbrothers.bsky.social2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
